MADRIGAL PHARMACEUTICALS, INC. — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| FRIEDMAN PAUL A | — | Sale | 7,193 | $551.67 | $3,968,162 | 198,887 | Dec 10, 2025 |
| Taub Rebecca | — | Sale | 369 | $548.56 | $202,419 | 478,834 | Dec 10, 2025 |
| Sibold William John | President and CEO | Sale | 2,400 | $575.34 | $1,380,816 | 150,074 | Dec 3, 2025 |
| Dier Mardi | EVP and CFO | Sale | 120 | $574.95 | $68,994 | 12,692 | Dec 2, 2025 |
| Huntsman Carole | Chief Commercial Officer | Sale | 40 | $553.23 | $22,129 | 10,552 | Nov 21, 2025 |
| Levy Richard S | — | Option Exercise | 6,000 | $16.46 | $98,760 | 29,697 | Nov 13, 2025 |
| BATE KENNETH | — | Sale | 1,931 | $484.78 | $936,110 | 8,896 | Nov 5, 2025 |
| Sibold William John | President and CEO | Sale | 7,279 | $445.63 | $3,243,741 | 102,474 | Sep 9, 2025 |
| Sibold William John | President and CEO | Sale | 1,131 | $401.00 | $453,531 | 109,753 | Aug 21, 2025 |
| Baker Bros. Advisors (GP) LLC | — | Purchase | 9,362 | $392.24 | $3,672,151 | 1,947,968 | Aug 18, 2025 |
| BAKER FELIX | — | Purchase | 2,747 | $369.34 | $1,014,577 | 1,843,469 | Aug 18, 2025 |
| Kelley Shannon T | General Counsel | Sale | 190 | $375.75 | $71,393 | 9,215 | Aug 18, 2025 |
| BATE KENNETH | — | Sale | 1,104 | $367.63 | $405,864 | 3,523 | Aug 15, 2025 |
| FRIEDMAN PAUL A | — | Sale | 4,155 | $374.38 | $1,555,549 | 187,164 | Aug 13, 2025 |
| FRIEDMAN PAUL A | — | Sale | 1,382 | $352.61 | $487,307 | 222,882 | Aug 11, 2025 |
| Taub Rebecca | — | Sale | 6,541 | $358.81 | $2,346,976 | 461,744 | Aug 11, 2025 |
| Brennan Daniel J. | — | Award / Grant | 967 | — | — | 967 | Aug 1, 2025 |
| Taub Rebecca | — | Option Exercise | 1,000 | $9.45 | $9,450 | 462,044 | Jul 18, 2025 |
| FRIEDMAN PAUL A | — | Option Exercise | 1,400 | $9.45 | $13,230 | 188,564 | Jul 18, 2025 |
| FRIEDMAN PAUL A | — | Sale | 700 | $351.57 | $246,099 | 187,164 | Jul 16, 2025 |
| Taub Rebecca | — | Sale | 1,380 | $356.52 | $491,998 | 461,044 | Jul 16, 2025 |
| BATE KENNETH | — | Award / Grant | 715 | — | — | 2,627 | Jun 20, 2025 |
| Levy Richard S | — | Award / Grant | 715 | — | — | 21,197 | Jun 20, 2025 |
| FOUSE JACQUALYN A | — | Award / Grant | 203 | — | — | 1,097 | Jun 20, 2025 |
| BAKER FELIX | — | Award / Grant | 1,430 | — | — | 188,837 | Jun 20, 2025 |
| Daly James M | — | Award / Grant | 715 | — | — | 2,627 | Jun 20, 2025 |
| FRIEDMAN PAUL A | — | Award / Grant | 715 | — | — | 187,164 | Jun 20, 2025 |
| Soergel David | Chief Medical Officer | Award / Grant | 7,545 | — | — | 7,545 | May 15, 2025 |
| Levy Richard S | — | Option Exercise | 9,470 | $65.06 | $616,118 | 20,482 | Apr 10, 2025 |
| CRAVES FRED B | — | Option Exercise | 1,728 | $65.06 | $112,424 | 351,804 | Mar 13, 2025 |
| Dier Mardi | SVP and CFO | Sale | 258 | $323.04 | $83,344 | 10,440 | Mar 10, 2025 |
| FOUSE JACQUALYN A | — | Award / Grant | 894 | — | — | 894 | Mar 10, 2025 |
| Sibold William John | President and CEO | Award / Grant | 13,066 | — | — | 117,369 | Mar 5, 2025 |
| Dier Mardi | SVP and CFO | Award / Grant | 3,784 | — | — | 10,698 | Mar 5, 2025 |
| Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sale | 1,043 | $341.84 | $356,539 | 10,918 | Mar 5, 2025 |
| Taub Rebecca | Pres., R&D, and CMO | Award / Grant | 4,382 | — | — | 461,044 | Mar 5, 2025 |
| Kelley Shannon T | General Counsel | Award / Grant | 3,187 | — | — | 10,477 | Mar 5, 2025 |
| Huntsman Carole | Chief Commercial Officer | Award / Grant | 3,386 | — | — | 11,990 | Mar 5, 2025 |
| Kelley Shannon T | General Counsel | Sale | 415 | $335.00 | $139,025 | 7,290 | Mar 3, 2025 |
| Dier Mardi | SVP and CFO | Sale | 774 | $323.54 | $250,420 | 6,914 | Mar 3, 2025 |
| Huntsman Carole | Chief Commercial Officer | Sale | 71 | $313.08 | $22,229 | 10,367 | Mar 3, 2025 |
| Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sale | 175 | $341.55 | $59,771 | 3,728 | Feb 28, 2025 |
| Sibold William John | President and CEO | Option Exercise | 50,000 | — | — | 104,303 | Feb 27, 2025 |
| Daly James M | — | Option Exercise | 9,470 | $65.06 | $616,118 | 11,382 | Feb 27, 2025 |
| BATE KENNETH | — | Option Exercise | 6,000 | $111.06 | $666,360 | 7,912 | Feb 27, 2025 |
| Huntsman Carole | Chief Commercial Officer | Sale | 347 | $335.24 | $116,328 | 10,438 | Jan 24, 2025 |
| Sibold William John | President and CEO | Sale | 1,584 | $335.24 | $531,020 | 54,303 | Jan 24, 2025 |
| Taub Rebecca | Pres., R&D, and CMO | Sale | 648 | $335.24 | $217,236 | 456,662 | Jan 24, 2025 |
| Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sale | 103 | $335.24 | $34,530 | 4,955 | Jan 24, 2025 |
| Kelley Shannon T | General Counsel | Sale | 277 | $273.41 | $75,735 | 7,705 | Jan 17, 2025 |